Pediatric Hematology Oncology Journal (Mar 2022)

Association between early risk factors and CDKN2A/B deletion in pediatric patients with acute lymphoblastic leukemia in a pediatric cancer center in Colombia

  • Cindy Martinez,
  • Luz Karime Yunis,
  • Edgar Cabrera,
  • Johnny García,
  • Gloria Uribe,
  • Edna Quintero,
  • Juan Jose Yunis,
  • Adriana Linares Ballesteros,
  • Isabel Cristina Sarmiento

Journal volume & issue
Vol. 7, no. 1
pp. 1 – 3

Abstract

Read online

Cyclin dependent kinase inhibitor (CDKN) 2A/B deletion is correlated with poor risk factors, such as high blood cell count, higher rate of induction therapy failure, and earlier relapses in pediatric patients with acute lymphoblastic leukemia (ALL). The frequency of CDKN2A/B deletion in the Hispanic population is not known. This study aimed to identify the frequency of CDKN2A/B deletion and explore the association of CDKN2A/B deletion with poor prognostic factors in Colombian pediatric patients with pre-B-ALL. One hundred and sixteen patients were included. Twenty-nine patients (25%) had CDKN2A/B deletion. CDKN2A/B deletions were associated with poor prognostic markers in this cohort.

Keywords